Cyclopropanecarboxylic Acid Amide

Cyclopropanecarboxylic Acid Amide

SCHEMBL2864932

NC(=O)C1CC1.O=C(O)c1ccc2[nH]nc(-c3cc4ccccc4o3)c2c1F

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 1/20 0.48
SIRT1 Q96EB6 1/20 0.48
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
VCP P55072 1/20 0.43
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
PIP5K1C O60331 1/20 0.38
KDM5A P29375 1/20 0.37
KDM4C Q9H3R0 1/20 0.37
KDM5B Q9UGL1 1/20 0.37
PLAU P00749 1/20 0.36
KCNH2 Q12809 1/20 0.36
SCN5A Q14524 1/20 0.36
JAK2 O60674 1/20 0.35
JAK3 P52333 1/20 0.35
KDR P35968 1/20 0.35
MAOB P27338 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2872600 0.90 KDM4E (0.45) SIRT2SIRT1NPC1RAB9AKDM4E
Cyclopropanecarboxylic Acid Amide SCHEMBL2861585 0.82 NPC1 (0.40) NPC1RAB9ASMN1; SMN2VCPKDR
SCHEMBL2864933 0.81 PIP5K1C (0.48) SIRT2SIRT1NPC1RAB9APIP5K1C
Cyclopropanecarboxylic Acid Amide SCHEMBL2857322 0.80 SIRT2 (0.48) SIRT2SIRT1PIP5K1CPLAUJAK2
SCHEMBL4341422 0.79 KDM4E (0.45) SIRT2SIRT1NPC1RAB9ASMN1; SMN2
SCHEMBL4341132 0.77 ALDH1A1 (0.41) SIRT2SIRT1NPC1RAB9AALDH1A1
SCHEMBL2872405 0.75 MAPT (0.41) SIRT2SIRT1KDM4EALDH1A1TDP1
SCHEMBL2865030 0.75 MAPT (0.41) SIRT2SIRT1NPC1RAB9ASMN1; SMN2
SCHEMBL4331298 0.74 KDM4E (0.42) SIRT2SIRT1NPC1RAB9ASMN1; SMN2
SCHEMBL13198297 0.73 TOP2A (0.49) SIRT2SIRT1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
EP-1380576-B1 1H-INDAZOLE COMPOUNDS INHIBITING JNK EISAI R&D MAN CO LTD (JP) 2009-11-25 EP disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-7541376-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-02 US disclosed
US-6982274-B2 1H-indazole compound EISAI CO., LTD. (JP) 2006-01-03 US disclosed
US-20050282880-A1 Novel 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-12-22 US disclosed
US-20040127538-A1 Novel 1h-indazole compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203691-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 SIRT2 1519/4885SIRT1 793/4885NPC1 1164/4885
US-20040127538-A1 Novel 1h-indazole compound MAPK1, MAPK14, MAPK3 SIRT2 2133/4885SIRT1 1299/4885NPC1 1171/4885
US-20050282880-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 SIRT2 1519/4885SIRT1 793/4885NPC1 1164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.